Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma.

Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and does not have sufficient prognostic indicators. (Fc fragment Of IgE receptor Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have shown that participates in many immune-related pathways encompassing multiple cell types. Meanwhile, it is associated with many malignancies. However, the relationship between MM and has not been studied. In this study, we integrated nine independent gene expression omnibus (GEO) datasets and analyzed the associations of expression and myeloma progression, ISS stage, 1q21 amplification and survival in 2296 myeloma patients and 48 healthy donors. The expression of showed a decreasing trend with the advance of myeloma. As ISS stage and 1q21 amplification level increased, the expression of decreased (P = 0.0012 and 0.0036, respectively). MM patients with high expression consistently had longer EFS and OS across three large sample datasets (EFS: P = 0.0057, 0.0049, OS: P = 0.0014, 0.00065, 0.0019 and 0.0029, respectively). Meanwhile, univariate and multivariate analysis indicated that high expression was an independent favorable prognostic factor for EFS and OS in MM patients (EFS: P = 0.006, 0.027, OS: P =0.002,0.025, respectively). The expression level of negatively correlated with myeloma progression, and high expression may be applied as a favorable biomarker in MM patients.